UCB SA - UNSPONSORED ADR Business Summary

UCB SA is a global biopharmaceutical company that generates revenue primarily through the development and commercialization of proprietary therapeutics for severe diseases, supplemented by royalty income and strategic licensing. The company’s business model is centered on two core Patient Value Units: Immunology, led by the rapid global expansion of the IL-17A/F inhibitor Bimzelx and the established TNF inhibitor Cimzia, and Neurology, which features a dominant epilepsy franchise including Briviact and Fintepla, alongside a burgeoning rare disease portfolio with Rystiggo and Zilbrysq. UCB competes directly with large-cap peers such as AbbVie, Novartis, and Sanofi. Within this landscape, UCB positions itself as a high-growth specialist that bridges the gap between niche orphan drug development and mass-market chronic disease management, particularly as it navigates the loss of exclusivity for legacy assets like Briviact in 2026 while scaling its biologics pipeline. The company is led by Chief Executive Officer Jean-Christophe Tellier, a veteran of Novartis and Ipsen whose mandate was renewed in 2026 to oversee UCB's next growth phase. The executive leadership team includes Chief Financial Officer Sandrine Dufour, who brings extensive financial expertise from the telecommunications sector, and Chief Scientific Officer Alistair Henry, who leads the firm's R&D engine. In January 2026, Fiona du Monceau transitioned to the role of Chief Commercial Officer to drive global market expansion. Founded in 1928 by Emmanuel Janssen, UCB’s governance remains anchored by the Janssen family, who maintain a significant controlling interest through the Financière de Tubize holding company. The Board of Directors is chaired by Jonathan Peacock, formerly of Amgen and Novartis, ensuring strategic alignment with long-term patient value and scientific innovation.